

The Neurology Center of Southern California
6010 Hidden Valley Road, Suite 200, Carlsbad, California 92011
9850 Genesee Ave, Suite 470, La Jolla, CA, 92037
1955 Citracado Pkwy, Suite 102, Escondido, CA 92029
15611 Pomerado Road, Suite 505 Poway, CA 92064

Phone: 760-631-3000
Fax: 760-631-3016



Jay Howard Rosenberg, M.D.

EDUCATION

Allegheny College, Meadville, PA ■ 1964
B.S.

Georgetown University School of Medicine, Washington, D.C. ■ 1968
M.D.

University of Southern California Medical Center
(LAC-USC Medical Center) Los Angeles, CA ■ 1968 - 1969
Internship, Rotating with Medical Emphasis

University of Southern California Medical Center
(LAC-USC Medical Center) Los Angeles, CA ■ 1969 - 1972
Residency, Neurology

LICENSURE

- California Medical License Number – G17059
-
-

CERTIFICATIONS

- Diplomat, American Board of Psychiatry and Neurology ■ 1975
 - National Board of Medical Examiners ■ 1969
-
-

RELATED EXPERIENCE

Neurologist, Private Group Practice, North County Neurology Associates dba The Neurology Center, Oceanside, CA ■ November 2002 – Present

PROFESSIONAL BACKGROUND

Visiting Professor and Locums Neurologist, University of Otago School of Medicine and Dunedin Public Hospital Otago Health Board, Dunedin NZ. Activities include multiple lectures to the professional staff, allied health professionals, and support groups in Dunedin and Invercargill NZ. Topics Headache, MS, and Brain Injury, June 25 – August 14, 2002.

Neurological Consultant to Serono Laboratories, Biogen Idec, and Teva Neuroscience, August 2001 to present. Multiple lectures around the country on MS including evidence, patient management, and empowerment of the patients.

PROFESSIONAL BACKGROUND CON

15/NOV/2012

Vice-President for Content and Professional Relations for Qyxis Software, an LLC that has developed "Health Headquarters," a PC product that helps patient organize and follow their medical condition. 540 Judson Avenue, Evanston, IL, 60202-3084 – October 2001 through June 2002.

Per Diem Consultant Neuro-oncology, Dept. of Neurology, Southern California Permanente Medical Group, San Diego, CA, October 5, 2001 – to present.

Staff Neurologist, Department of Neurology, Southern California Permanente Medical Group (SCPMG), 1972 – August 30, 2001.

Chief of Department of Neurology, SCPMG, San Diego, California March, 1973 - July 1, 1990.

Chief Resident, Department of Neurology, LAC-USC Medical Center, six months of academic year 1971 - 1972

Senior Supervising Ward Resident, Department of Neurology, LAC-USC Medical Center six months of academic year 1971-1972

Research Assistant, National Heart Institute, Department of Surgery, Cardiac Pathology, June - August 1966

Summer Extern, Veterans Administration Hospital, Department of Physical Medicine and Rehabilitation, Perry Point Maryland, June to August 1965.

HOSPITAL AFFILIATIONS

- **Tri-City Medical Center**, Oceanside, California, Active Privileges ■ 2002 - Present
 - **Scripps Memorial Hospital**, Encinitas, California, Active Privileges ■ 2002 – Present
 - **Scripps Memorial Hospital**, La Jolla, California, Active Privileges ■ 2002 – Present
-
-

MEMBERSHIPS

Member, Council for Ethical Affairs, California Medical Association, 2006

Fellow, American Academy of Neurology (AAN) December 1988 - present

President, Society of Clinical Neurologists, 1990-1991

Member, Society of Clinical Neurologists, 1978 - present

President, San Diego Neurological Society, President 1976 - 1978

Member, San Diego Neurological Society 1972 - Present

Member, San Diego County Medical Society (SCDMS) - 1985 - present

Member, American Medical Association 1985 - Present

Member, American Epilepsy Society 1990 - Present

Member, Consortium of Multiple Sclerosis Societies

Member, Brain Injury Association

VOLUNTARY BOARD MEMBERSHIP

15/NOV/2012

Member, Board of Directors Brain Injury Association of America—May 1998 - Present

Member, Medical Advisory Board, Epilepsy Society of San Diego - 1993 - 1997

Medical Advisory Board to the California State Department of Motor Vehicles January 1990 – 1997 (Disbanded)

Member, of Task Force to establish Guidelines for Patients reported because of Lapses of Consciousness March - June 1991

Chairman, Medical Advisory Board and Member of the Board of Directors Multiple Sclerosis Society San Diego Chapter, January 1986 - January 1989

Member, Board of Directors, San Diego Heart County Association, January 1983 -January 1986 and Chairman, Stroke Committee, San Diego County Heart Association 1983 - 1984

Medical Advisor, San Diego Chapter, Committee to Combat Huntington's Disease (Present known as the Huntington's Disease Foundation of America) 1982 - 1983

Member, Board of Trustees, Committee to Combat Huntington's Disease, 1982 - 1984

Member of the Neurology California Medical Association Advisory Board 1980 - 1981

SCPMG PROFESSIONAL ACTIVITIES

“Recent Advances in the Treatment of Multiple Sclerosis.” November 30, 1997

Medicine in the Nineties, April 10, 1997, Treatment of Stroke Teleconference in Oakland, CA

Co-Chairman, 22nd Annual Neurology Symposium, "Practicing with Probabilities: Using the Literature to Make Rational Recommendations" - Saturday, March 11, 1995, Costa Mesa, Ca.

Chairman, Symposium, "Facing the Challenges of 1980's in our HMO", SCPMG, Anaheim, 1986

Member of the Advisory Panel to the Home Health Agency 1985 - 1989

Chairman, Ad hoc Regional Incentive Committee, September 1986 - October 1987. Regional Committee of Seven Areas to explore possibility of restructuring of physician payment system.

Member, Bioethics Committee, Kaiser Foundation Hospital San Diego 1983 - February 1991

Co-Chairman of the Joint Practice Committee Kaiser Foundation Hospital San Diego 1977-79

Member, Utilization Review Committee, Kaiser Foundation Hospital 1973 - 1977

Member, Ad hoc Task Force to Examine the Care of Terminal Patients March - June 1980

Chairman, Pediatric Neurology Symposium, Vacation Village Hotel, SCPMG, April 1975

Member of the Task Force to Reorganize the Department of Psychiatry and Community Medicine
1975 - 1976

ACADEMIC ACTIVITIES

15/NOV/2012

Clinical Professor of Neurology, Department of Neuroscience, Division of Neurology, University of California San Diego (UCSD) School of Medicine

Two weeks per year attending VAH Consult and Ward Service - 1995 - 2002

One month per year attending VAH Neurology Ward Service - 1974 -1994

One month per year attending VAH Clinic - 1975 - 1982

Faculty, SBS Freshman Course 1983 - 1985

Member of Admissions Committee, School of Medicine, UCSD 1977 - February 1992

Member of the Executive Admissions Committee UCSD School of Medicine 1984 - 1992

Visiting Professor, Department of Medicine Division of Neurology, Otago University School of Medicine, Dunedin, New Zealand, June - August 1979

PROFESSIONAL ACTIVITIES

Member of Board of Directors, American Academy of Neurology, May 2001 to 2003

Chairman of Board of the American Academy of Neurology Education and Research Foundation
May 2001 to May 2003

Permanent Ex-Officio Member, Quality Standards Subcommittee, American Academy of
Neurology, April 1995 to present.

Member, Practice Enhancement Taskforce of the Practice Committee April 1999 to present

Chairman, Public Education Committee for the AAN ERF April 1999 to May 3, 2001

Member, Board of Directors, American Academy of Neurology Education and Research
Foundation (ERF) April 1999 to April 2009

Member, Board of Directors American Academy of Neurology, April 1995 to April 1999.

Member, Implementation and Outcomes Subcommittee, American Academy of
Neurology, April 1997 to April 1999.

Member, Computer Committee, American Academy of Neurology, July 1995 to Present

Chairman, Quality Issues Working Group. American Academy of Neurology, 1995 to 1997.

Chairman, Dissemination, Implementation and Outcomes Subcommittee, American Academy of
Neurology, July 1995 to July 1997

Member, San Diego County Medical Association Ad hoc Committee on "Physician Assisted
Suicide," July 1, 1993 to present.

Member, American Academy of Neurology Ad hoc Committee on "Code of Ethics for the AAN."
February 4, 1993, Disney Hilton Hotel, Orlando, Florida.

Member, Bioethics Committee, San Diego County Medical Society, January 1985 - 1993

PROFESSIONAL ACTIVITIES

Chairman, Bioethics Committee, San Diego County Medical Society,
1990

15/NOV/2012

Member, Practice Committee, AAN July 1985 - July 1995

Ad Hoc Member, Practice Committee, July 1995-July 1997

Chairman, Quality Standards Subcommittee, AAN April 1989 - May 1995

Member, Legislative Affairs Subcommittee, AAN January 1987 - April 1993

Member, Professional and Public Information Committee, January 1987 - April 1993

Member, Neurological Education of Non Neurologists Subcommittee, April 1987 - April 1993

Member, Physician Reimbursement/Economics Subcommittee, April 1989 - April 1991

Technical Consulting Panel Member, Harvard Resource-Based Relative Value Scale Study,
November 30 and December 1, 1988, Boston, Massachusetts

Program Chairman, Western Federation of Neurological Societies, February, 1981, San Diego,
California

PROFESSIONAL PRESENTATIONS

Multiple lectures around the country on MS including diagnosis, etiology, epidemiology, treatment, patient management, and empowerment of the patients for Bayer, Biogen Idec, Teva, and EMD Serono from 2003 to present.

"Coping with MS: Our Personal Story." Presented to the MS Society Invercargill, New Zealand, August 10, 2002

"Coping with MS: Our Personal Story." Presented to the MS Society, Dunedin, New Zealand, August 2, 2002

"Coping with MS: Our Personal Story." Presented to the MS Society, Johannesburg South Africa, September 29, 2001

"Sports Related Concussion—American Academy of Neurology Guidelines." Presented to Society of Clinical Neuropsychology of South Africa Annual Meeting, Capetown, South Africa, September 9, 2001, as part of a "Sports Related Concussion Symposium."

"Dementia Guidelines of the American Academy of Neurology—An evidence based approach." Presented to Society of Clinical Neuropsychology of South Africa Annual Meeting, Capetown, South Africa, September 8, 2001.

“Fatigue in the Central Nervous System.” Presented to the Society of Clinical Neuropsychology of South Africa Annual Meeting, Capetown, South Africa, September 7, 2001.

“Coping with MS: Our Personal Story.” Presented to the MS Society, Capetown South Africa, September 5, 2001.

PROFESSIONAL PRESENTATIONS COI

15/NOV/2012

“Brain Injury in Sports and Recreation.” Presented to the Physical Education Department, University of Western Cape, Capetown South Africa, Wednesday September 5, 2001.

“Brain Injury in Sports and Recreation.” Presented at the Concussion in Sports and Recreation Conference: Prevention, Assessment, Resources, Sponsored by the Brain Injury Association of Kansas and Greater Kansas City, Saturday, January 23, 1999, Black & Veatch’s Ruisch Auditorium, Overland Park, Kansas.

“Enhancing Your Practice.” Presented as Faculty at the Annual Regional Course of the MEM Subcommittee of the American Academy of Neurology, Sunday July 18, 1999 9:00-12:00 Hyatt West Dallas Fort Worth Airport.

“Cases and Management of Sports Related Concussions.” Presented at the Annual Oklahoma Athletic Trainers Association Meeting, Saturday, July 17, 1998, 2:00 – 3:00 PM, Hyatt, Tulsa Oklahoma.

“Mild Traumatic Brain Injury Guideline Development Process: A Report of the Aspen Group.” Presented at the European Federation of Neurology Mild Traumatic Brain Injury Symposium, Seville, Spain, September 20, 1998 4:00-6:00 PM.

“When to Return to Play following a Concussion,” Presented to the Coaches of the Escondido High School District, Saturday August 15, 1998 8:00-10:00 AM, Escondido School District Office.

“When to Return to Play following a Concussion,” Presented at Nebraska Brain Injury Association Sports Related Concussions, Lincoln Nebraska, July 31, 1998, 10:00-12:00 AM.

“Sports Related Concussion.” Presented to the Neurology Grand Rounds, San Francisco Pacific Medical Center, July 30, 1998 12:00-1:30 PM.

“Sports Related Concussion.” Presented at the Dinner seminar at 50th Annual Meeting of the American Academy of Neurology, Minneapolis, Minnesota, Friday, May 1, 1998 6:00 – 9:00 PM.

“Speakers Bureau Workshop” Presented at the Dissemination of Sports Related Concussion. 50th Annual Meeting of the American Academy of Neurology, Minneapolis, Minnesota, Wednesday afternoon April 29, 1998 1:00 – 5:00 PM.

“Evidence Based Practice Guidelines for the Management of Migraine Headache.” Dinner Seminary for the AHCPR Headache Practice Guideline Project, 50th Annual Meeting of the American Academy of Neurology, Minneapolis, Minnesota, Monday April 27, 1998 6:00 – 9:00 PM.

“Enhancing your Practice,” Practice Enhancement Course Faculty, 50th Annual Meeting of the American Academy of Neurology, Minneapolis, Minnesota, Saturday April 25, 1998 1:00 – 5:00 PM.

“Sports Related Concussion,” Presented at the National Brain Injury Association Conference, Marriott, Philadelphia, Pennsylvania, November 3, 1997 1:00-5:00 PM.

“When to Return to Sports after a Concussion.” Presented at the BIA of Canada Course on Sports Related Head Injury, Landmark Hotel, Vancouver, British Columbia, October 17, 1997 10:00-11:00 AM.

PROFESSIONAL PRESENTATIONS CO

15/NOV/2012

“Sports related Concussion” Presented at the 2nd Annual BIA Legal Course at the Fairmont Hotel, San Francisco, September 26, 1997 10:00-11:00 AM.

“Headache Guidelines.” Presented at the 39th Annual Scientific Meeting of the American Association for the Study of Headache, The Waldorf-Astoria Hotel, New York, New York, June 22, 1997, 10:45-11:30 AM.

“Quality of Life in People Receiving Betaferon Therapy.” At the Satellite Symposium of the 7th European Neurological Society Congress entitled: Betaferon: Therapy in Multiple Sclerosis – Building on Experience Monday, 16 June 1997 1930-1950 hours.

“Scope of the Project: History, Process & Organization.” At the Mini-Symposium: “International Evidence Based Guidelines for Headache Management” 8th Congress of the International Headache Society, 10-14 June 1997, Amsterdam, The Netherlands delivered June 14, 1997, 1905-1915 hours.

“Levels of Concussion and Guidelines: When to Return to Sports following a Concussion?” delivered at the Concussion in Sports and Recreation Symposium Charlotte Marriott City Center, Charlotte, NC. June 5, 1997 10:00-10:30 AM.

Co-Chairman, Symposium: Concussion in Sports and Recreation. Annual Membership Meeting of the Brain Injury Association, June 5-7-1997 at the Charlotte Marriott City Center, Charlotte, NC.

Co-Chairman, “Evidence Based Medicine: AHCPD Guideline Development” Breakfast Seminar # 319 April 18, 1997 at the American Academy of Neurology 49th Annual Meeting, April 12-19, 1997, Boston, MA.

“Guidelines for When to Return to Sports Following a Concussion.” Presented at the Second World Congress on Brain Injury: Advances in Neurotrauma from Research to Community Living, Hotel Melia Los Lebreros, Seville, Spain, May 14, 1997, 11:30-1:00 PM.

Chairman, Session on Sports and TBI At the Second World Congress on Brain Injury: Advances in Neurotrauma from Research to Community Living, Hotel Melia Los Lebreros, Seville, Spain, May 10-14, 1997.

Co-Chairman, International Working Group to achieve consensus on the diagnosis and management of patients in the Vegetative/Minimally Conscious State: Critique of the Aspen Document. At the Second World Congress on Brain Injury: Advances in Neurotrauma from Research to Community Living, Hotel Melia Los Lebreros, Seville, Spain, May 8-9, 1997.

“Development of Practice Parameters by the AAN.” At the Course # 237 Neurology Practice Parameters From Concept to Final Recommendations April 14, 1997, 2:15-6:00 PM at the American Academy of Neurology 49th Annual Meeting, April 12-19, 1997, Boston, MA.

“Sports Related Concussion.” San Diego 911 Conference, Sheraton Pointe Hotel, January 24, 1997 1:15-4:00PM.

"Betaseron in the treatment of Multiple Sclerosis." Delivered at the Annual Meeting Research Progress and Promise, National Multiple Sclerosis Society, Southern California Chapter Annual Meeting, Sunday, November 17, 1996, 10:00-12:00 noon, Pasadena Hilton Hotel.

PROFESSIONAL PRESENTATIONS CO

15/NOV/2012

"Chemotherapy in the treatment of Primary Brain Tumor." Delivered Brain Tumor Association, Saturday, November 16, 1996 3:00-4:00 PM. La Jolla Marriott, La Jolla Ca.

"The Science and Politics of Practice Guidelines for Acquired Brain Injury: A Multi-Specialty Report from the Aspen Neuro-Behavioral Institute." At The Annual Meeting of the American Academy of Physical Medicine and Rehabilitation/American Congress of Rehabilitation October 12-14 1996, Hilton Towers, Chicago, Illinois, delivered October 13, 1996,

"Development of Practice Guidelines: Concepts and Methodologies." An Interdisciplinary Panel Discussion sponsored by the Advisory Council for Neurological Surgery delivered at the 1996 Annual Meeting of the American College of Surgeons, October 8, 1996, Moscone Center, San Francisco, California.

"Closed Head Injuries: Sideline Assessment of the Head Injured Player. Delivered April 25, 1996. "National Athletic Trainers Research & Education Foundation Sponsored Talk. Far West Athletic Trainers Association Clinical Symposium, April 25-29, 1996, Town & Country, San Diego, Ca. "Psychosocial Aspects/Legal Issues: Driving and Epilepsy." Delivered to UCSD, The Many Faces of Epilepsy: Refining the Diagnosis and Optimizing Management. April 20, 1996, The Sheraton Grande Torrey Pines, San Diego, Ca.

"Strategies for Guideline Development." Annual Course on the development of Practice Parameters. Friday, March 29, 1996 at the American Academy of Neurology Annual Meeting 1996, Moscone Center, San Francisco, Ca.

"Outcome Activity for 1995-96." Addressed to the Corporate Round Table of the American Academy of Neurology Research and Education Foundation, Wednesday, March 27, 1996, at the American Academy of Neurology Annual Meeting 1996, Moscone Center, San Francisco, Ca.

"Educating the Physician in a Managed Care Environment." AB Baker Colloquium. Monday, March 25, 1996 at the American Academy of Neurology Annual Meeting 1996, Moscone Center, San Francisco, Ca.

"Guidelines in the 1990's: Definition and Implications." Tulsa Neuroscience Society, November 7, 1995, Tulsa, Oklahoma.

"Recent Developments in the Management of Multiple Sclerosis," Sponsored by the Texas Tech University Health Science Center and St. Mary's Neurological Research Institute, Plaza Holiday Inn, Lubbock, Texas, Wednesday, September 27, 1995, 6:00-9:00 PM.

"Paradigms of Care: Management of the Vegetative State Patient," Jay Rosenberg MD, Nathan Zasler, M.D. and Joe Giacino, Ph.D., Presented at the American Congress of Rehabilitation Medicine, 1995 Annual Meeting, Hyatt Regency, Crystal City, June 23, 1995, 4:30-6:00 PM.

"When to Return to Sports from a Concussion?" Annual Meeting of the Southern California Trainers Association, San Diego State Football Operations, December 5, 1994.

"A Practical Approach to Bioethics," Visiting Lecturer, California Western School of Law, Bioethics and Law, September 19, 1994.

"Guideline Development and its Future in Medicine," Visiting Lecturer, UCSD Sophomore Class, SBS Course, November 1, 1994.

"When Does a Persistent Vegetative State Become Permanent?" Neurology Grand Rounds, UCSD Medical Center, July 8, 1994

"Symposium on the Diagnosis, Management and Evaluation of the Persistent Vegetative State." 1994 Annual Meeting of the National Head Injury Foundation, November 7, 1994, Chicago, Ill.

"Controversies in the Management of Supratentorial Low-Grade Gliomas: The Neurologists Perspective." Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO), San Francisco Musconi Center, October 3, 1995.

"Practice Parameters and Practice Guidelines." House of Delegates New Hampshire Medical Society, Clarion Sommerset Hotel, Nashua, New Hampshire, January 23, 1993,

"Extremes of Care." AMA Parameters Forum at the Hotel Sofitel, Rosemont Illinois, November 20, 1992.

"Practice Parameters in the 90s: What is a parameter and who are the key players?" Case Screening Guidelines Committee at the Annual Meeting of the Congress of Neurosurgery, Washington Sheraton, November 2, 1992.

"Developing Guidelines for Multiple Sclerosis," Medical Advisory Board of the National Multiple Sclerosis Society at Annual Meeting of the American Academy of Neurology, Marriott at the Marina, San Diego, California May 6, 1992 12:00 - 1:30 PM

"Guideline Development in the 1990s," Medical Advisory Board of the Epilepsy Foundation of American and the Guidelines Committee of the Epilepsy Foundation of America as well as a presentation to the Practice Committee of the American Epilepsy Society at the Annual Meeting of the American Epilepsy Society, Hotel Wyndem at Franklin Plaza, Philadelphia, Pennsylvania December 10, 1991 8:00 - 10:00 AM and 12:00 - 1:30 PM.

"When to drive following a first generalized tonic-clonic seizure." California Association of County Public Health Officers, Bay Club Hotel and Marina, Shelter Island, San Diego, California October 31, 1991 9:00 - 10:00 AM.

"When to return to play following a first sport's concussion--the anatomy of a parameter," Society of Clinical Neurologists, Grinbakken Lodge, Tahoe City, California, September 11-14, 1991

"Update on the guideline for driving and epilepsy," Medical Advisory Board, San Diego Epilepsy Society of San Diego County, July 29, 1991, 12:00 - 1:30

"Diagnosis and Differential of Dementia--A Discussion of Pertinent Ethical Issues," San Diego Chapter of the Hemlock Society, San Diego Unitarian Church, July 7, 1991, 2:00 PM

"Probability of having a seizure while driving in the immediate 6 months following a driving restriction." Conference on Driving and Epilepsy, American Academy of Neurology and Epilepsy Foundation of America, Raddison Hotel, Alexandria Virginia, May 31-June 3, 1991.

PROFESSIONAL PRESENTATIONS C

15/NOV/2012

"Eosinophilic Myalgia Syndrome Plus", 30th Annual Meeting of the Society for Clinical Neurologists, October 19-23, 1990, Grand Marriott Hotel, Point Clear, Alabama.

"Driving in the Elderly", 30th Annual Meeting of the Society for Clinical Neurologists, October 19-23, 1990, Grand Marriott Hotel, Point Clear, Alabama.

Hemlock Society, San Diego Chapter, "Preparing Your Durable Power of Attorney for Health Care: Neurological and Medical Aspects", Sunday, July 8, 1990, San Diego Unitarian Church

Chairman, SDCMS Bioethics Workshop, "Identifying the Key Bioethical Issues Facing San Diego in the 1990s", January 20, 1990 San Diego

Faculty Member, "Appropriate Utilization of Neurological Consultation", workshop presented at the American Academy of Family Practice Meeting, September 19, 1989, Los Angeles, California

Chairman, Workshop, "Appropriate Utilization of Neurological Consultation", American Association Internal Medicine (ASIM) Annual Meeting, October 14, 1988 Atlanta, Georgia

AAN After Dinner Seminar Faculty, "Patterns of Neurologic Practices" April 1988, AAN Annual Meeting, Cincinnati, Ohio

AAN Breakfast Seminar Faculty, "HMO's, PPO's and DRG's and Regulations on Practice", AAN Annual Meeting, May 1986, New Orleans, Louisiana

AAN Dinner Seminar Chairman, "Management of the Dying Patient", AAN Annual Meeting, April 1985, Dallas Texas

AAN Dinner Seminar Chairman, "Coping with Chronic Neurological Illness", AAN Annual Meeting, April 1984, Boston, Massachusetts

Chairman, Workshop entitled, "Coping With Huntington's Disease", Annual Meeting Committee to Combat Huntington's Disease, August 1983

PAPERS

J.T. Giacino, S. Ashwal, N. Childs, R. Cranford, B. Jennett, D.I. Katz, J.P. Kelly, J.H. Rosenberg, J. Whyte, R.D. Zafonte, and N.D. Zasler. "The minimally conscious state: Definition and diagnostic criteria." *Neurology* 2002 58: 349-353.

K W Rammohan, J H Rosenberg, D J Lynn, A M Blumenfeld, C P Pollak, and H N Nagaraja. "Efficacy and safety of modafinil (Provigil®) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study." *J Neurol Neurosurgery Psychiatry* 2002; 72: 179-183

Kelly J and Rosenberg JH. "The Development of Guidelines for Management of Concussion in Sports." *J Head Trauma Rehabilitation* 13(2):53-65, 1998.

Quality Standards Subcommittee of the American Academy of Neurology, Facilitator and Author of summary statement. Practice Parameter: When to return to play following a concussion.
Neurology 48(3):581-585, 1997.

15/NOV/2012

PAPERS CONTINUED

Kelly J and Rosenberg JH. "Diagnosis and Management of concussion in Sports." *Neurology* 48(3):575-580, 1997.

Rosenberg JH and Ashwal S. □Recent advances in the development of practice parameters: The Vegetative State. □ *Neurorehabilitation* 6(1):79-87, 1996.

Quality Standards Subcommittee of the American Academy of Neurology, Dr. Jay Rosenberg, Author and facilitator. □Practice Parameter: A guideline for discontinuing antiepileptic drugs in seizure-free patients--Summary Statement □ *Neurology* 47:600-602 August 1996:

Quality Standards Subcommittee of the American Academy of Neurology, Chairman, Dr. Jay Rosenberg. "Practice parameters: Assessment and management of patients in the persistent vegetative state (Summary Statement)." *Neurology* 45(5):1015-1018, May 1995.

Cranford, Ronald M.D., Ashwal, Stephen M.D., and Rosenberg, Jay, M.D. "Commentary on the practice parameters for the persistent vegetative state." *Neurology* 45(5):859-860, May 1995.

Rosenberg, Jay M.D. and Greenberg, Mike M.D. "Practice Parameters: Strategies for survival into the nineties." *Neurology* 42(5):110-115, May 1992.

Quality Standards Subcommittee of the American Academy of Neurology, Chairman, Dr. Jay Rosenberg. "Practice Guidelines: Neurological evaluation". *Neurology*, June, 1990, (40) 6:871.

Rosenberg, Jay and Roberts, William C., M. D. "Double Orifice Mitral Valve; Study of the anomaly in the Two Calves and a Summary of the Literature in Humans". *Archives of Pathology* 86:77-80, July 1968.

Ashwal S, Cranford RE, Rosenberg JH. Commentary on the practice parameters for the persistent vegetative state. *Neurology*. 1995 May; 45(5):859-60. No abstract available. PMID: 7746396; UI: 95265185

Katz B, Rosenberg JH. Botulinum therapy for apraxia of eyelid opening.

Am J Ophthalmol. 1987 May 15; 103(5):718-9. No abstract available. PMID: 3578473; UI: 87210490

Raasch FO, Rosenberg JH, Abraham JL. Lead poisoning from hair spray ingestion. *Am J Forensic Med Pathol*. 1983 Jun; 4(2):159-64. MID: 6859003; UI: 83228047

Sipe JC, Rosenberg JH. Granulomatous giant cell angitis of the central nervous system. *West J Med*. 1977 Sep; 127(3):215-20. No abstract available. PMID: 20694; UI: 78015590

POSTER PRESENTATIONS

Likosky W, Rosenberg JH. "A Model System for Centers of Excellence for MS in a HMO." European Consortium for the Treatment and Research in MS. ECTRIMS, Basel, Switzerland, September 1998.

POSTER PRESENTATIONS CONTINUED

Rosenberg, JH and Gordon F. "Rebaject Improves Quality of Life of Patients on Rebif." European Consortium for the Treatment and Research in MS. ECTRIMS Milan, Italy, September 1999.

Rosenberg JH, Powell H, Meyer L, Noronha A. Multiple sclerosis : cerebral autosomal dominant arteriopathy with subcortical infarcts (cadasil) : neither : or both—a new variant notch 3 mutated cadasil gene! The European Consortium for Treatment and Research in MS (ECTRIMS) October 14-17 2007 Praque, Czeck Republic.

Rosenberg JH and McDonough M. "Diffuse Axonal Injury Correlation with Neuroimaging and Neuropsychological Testing" The North American Brain Injury Society's Fifth Annual Conference on Brain Injury San Antonio, Texas. September 27-29. 2007

Rosenberg JH and Olmstead D. "A review of Leo Kanner's Original Cohort of 11 Autistic Cases with Long Term Follow up of 7 cases." American Academy of Neurology Annual Meeting 2009 Seattle, Washington.

Rosenberg JH and Blumenfeld AM. "Acute Intermittent Porphyria: The enigma of a chronic Pain Syndrome—a high level of diagnostic suspicion, vigilance and close follow-up sometimes results in an alternative diagnosis." American Academy of Neurology Annual Meeting 2010 Toronto, Canada.

PROFESSIONAL POST GRADUATE EDUCATION

Biomedical Ethics 7 day course University of Washington, Seattle August 3-7, 2009.

"AMA Political Action Conference," October 2-3 1991, JW Marriott, Washington, D.C.

"The Explicit Approach to Practice Policy Development", Dr. David Eddy, Jackson Hole, Wyoming, June 4 through June 8, 1990.

"The Explicit Approach to Practice Policy Development II", Dr. David Eddy, Jackson Hole, Wyoming, September 4-9, 1990.

"Mini fellowship in Epilepsy", The Bowman Gray School of Medicine of Wake Forest University, July 14 through July 20, 1990.

"Professional Leadership Development", Colorado Outward Bound, Green River, Utah, July 4 though July 9, 1990

"Professional Leadership Development", Colorado Outward Bound, Leadville, Colorado, July 22 through July 27, 1987

RESEARCH ACTIVITIES

Principle Investigator - "Serona Head to Head Study of Avonex versus Rebif in the treatment of Relapsing and Remitting Multiple Sclerosis."

RESEARCH ACTIVITIES CONTINUED

Principle Investigator – “Betaseron Secondary Progressive MS Trial”. Berlex Laboratories, 1995-2000.

Principle Investigator—“CHAMPS Trial”. Biogen Laboratories, 1997-2000.

Principle Investigator—“A Multi-Center, Single-Blind Clinical Trial to Assess Safety and Efficacy of the Treatment of Fatigue in Multiple Sclerosis with Provigil (Modafinil), Aug. – Dec. 1999.

Sub-Investigator- 065-00- (Maxalt) “A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10-mg Tablet Administered Early During a Migraine Attack While the Pain is Mild”, Sub-Investigator, 2004

Sub-Investigator- MT400-301 (POZEN) “A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study To Evaluate The Safety And Efficacy Of Trexima In The Acute Treatment Of Migraine Headaches”, Sub-Investigator, 2004

Sub-Investigator- 9006- (TEVA) “A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of 40mg of Copaxone in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients”, Sub-Investigator, 2004

Sub-Investigator- SA-NXY-0012- (CHANT) “A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb Study to Assess The Safety And Tolerability Of 72 Hours Intravenous Infusion of NXY-059 In Adult Patients with Intracerebral Hemorrhage (ICH)”, Sub-Investigator, 2004

Sub-Investigator- 1198.100 “A 14-week placebo-controlled dose-response efficacy and safety study of NS 2330 in Early Parkinson’s Disease patients (Study of the Concept of treating Early Parkinson’s Disease with a Triple Reuptake inhibitor, NS 2330) [SCEPTRE]” Sub - Investigator – 2004

Sub-Investigator- GAL-COG-3002- “An Analysis of Mortality in Subjects who Participated in Three Studies of Galantamine in Mild Cognitive Impairment”, Sub-Investigator, 2004

Sub-Investor- Ptl-01213 entitled: “A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel study to evaluate the effects of DP-b99 on Neurologic Function and Disability in subjects with Acute Ischemic Hemispheric Stroke, 2004

Sub-Investigator- TVP1012-A001-201- A 1-Year, double-blind, randomized, placebo-controlled study of Rasagiline 1 mg and 2 mg added to Aricept 10 mg daily in patients with mild to moderate dementia of the Alzheimer’s type. 2005.

Sub-Investigator- 001 – “A Randomized, Evaluator-Masked Trial to Evaluate the Efficacy of Botox Compared with Depakote in Migraine Prevention”

Sub-Investigator- E2007-A001-210- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 in Migraine Prophylaxis. 2005.

RESEARCH ACTIVITIES CONTINUED

Sub-Investigator- A Single-Center, Double-Blind Comparison of BOTOX® (Botulinum Toxin Type A) and DEPAKOTE® for the Prophylactic Treatment of Migraine Headaches- Pilot Study.

Sub-Investigator- 9.159 PRoFESS- Prevention Regimen For Effectively avoiding Second Strokes: A double-blind, active and placebo controlled study of Aggrenox® vs. clopidogrel, with and without Micardis

Sub-Investigator- SA-NXY-0007: “A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke”.2004

Sub-Investigator - F7ICH-1641 A Randomized, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niasase® in Acute Intracerebral Hemorrhage, 2004

Sub-Investigator - 101468/205: A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients with Restless Legs Syndrome, 2005

Sub-Investigator: - E2020-A001-412: A One Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride (E2020) in Subjects with Mild Cognitive Impairment, 2005

Sub – Investigator -1602 “Occipital Nerve Stimulation (ONS) for the Treatment of Chronic Migraine Headache” - 2005

Sub-Investigator - NTI-ASP-0502 “A Randomized, Double-Blind, Placebo Controlled Study of Ancrod (Viprinex) in Subjects Beginning Treatment within 6 Hours of the Onset of Acute Ischemic Stroke”. 2006

Sub-Investigator - CD-0125 “Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke”. 2006

Sub-Investigator - VP-AD-301 “A Double-Blind Placebo-Controlled Study of VP4896 for the Treatment of Mild to Moderate Alzheimer’s Disease”. 2006.

Sub-Investigator – PRX-03140 “A Randomized, Double-Blind, Placebo Controlled, Phase IIa Study to assess the Short-Term Effects of PRX-03140 Alone and in Combination with Donepezil in Subjects with Mild Alzheimer’s Disease.” 2006

Sub Investigator – E2080-A001-301 “A Double-Blind, Placebo Controlled, Parallel Group Study of Rufinamide Give as Adjunctive Therapy in Patients with Refractory Partial Seizures.” 2006

Sub-Investigator – TRX103632/635 “A Randomized, Double-Blind, Multi-Center, Placebo Controlled, Cross-Over Study to Determine the Consistency of Response for TREXIMA (Sumatriptan 85mg/Naproxen Sodium 500mg) in the Acute Treatment of Multiple Migraine Attacks.” 2006

RESEARCH ACTIVITIES CONTINUED

Sub-Investigator – TRX106573 “A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Cross-Over Study of Trexima® in Migraine subjects Who Report Poor Response or Intolerance to Relpax®.” 2006

Sub-Investigator – S308-3-003 “A Multi-Centre, Randomized Double-Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson’s Disease.” 2006

Sub-Investigator – 28821 “A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Oral Cladribine in Subjects with a First Clinical Event at High Risk of Converting to MS.” 2006

Sub-Investigator – A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis with optional extension phase ProtocolNo.: CFTY720D2309
Extension to CFTY720D2309 (A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5mg and 1.25mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis. “2006

Sub-Investigator – NL-2006-001 “A Phase III Randomized, Double-Blind, Parallel Group, Sham-Controlled Study Evaluating the Efficacy and Safety of Non-Invasive, Non-Repetitive Transcranial TMS Stimulation (TMS) for the Acute Preemptive Treatment of the Aura Phase of Migraine Headache.” 2007

Sub-Investigator - NTS-INT06-007 “A Double-Blind, Randomized, Controlled, Parallel Group, Multi-Centre, Pivotal Study to Assess the Safety and Effectiveness of the Treatment of Acute Ischemic Stroke with the NeuroThera® Laser System within 24 Hours from Stroke Onset. “ 2007

Sub-Investigator – TON/03/07-CLIN “A Multi-Centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache and Open Label Extension.” 2007

Sub-Investigator - MPB8298-SP-03 “A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis.” 2007

Sub-Investigator - S308-3-008 “An extension of SLV308, A multicenter, randomized, double-blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of monotherapy in the treatment of patients with early stage Parkinson’s disease.” 2007

Sub-Investigator - A 12-month double-blind, randomized, multicenter, active-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus interferon β -1a (Avonex®) administered i.m. once weekly in patients with relapsing-remitting multiple sclerosis with optional Extension Phase, “ 2007

RESEARCH ACTIVITIES CONTINUED

Sub-Investigator - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH530348 in Addition to Standard of Care in Subjects With a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50) P04737-3694, “ 2007

Sub-Investigator – ELN115727-301 & 302 “A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AA-001,

Sub-Investigator - ELN115727 in Patients with Mild to Moderate Alzheimer’s Disease who are Apolipoprotein Eε4 Non-Carriers (301) or Non-Carriers (302), 2008

Sub-Investigator – ELN 115727-351 “A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Alzheimer’s Disease who Participated in Study ELN115727-301 or in Study ELN115727-302” 2009

Sub-Investigator – P04737 “A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a history of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events”, 2008

Sub-Investigator - ACT 10573 “A Double Blind, Placebo-Controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispiridine on Visual Function in Patients with Multiple Sclerosis” – 2008.

Sub-Investigator – “A Randomized, Double-blind, Placebo Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Botulinum Neurotoxin Type A in the Treatment of Forward Head Posture with Associated Chronic Tension Type Headache using a Novel Fixed site Injection Paradigm” 2009

Sub-Investigator - BTX0805 “Safety and Efficacy of Botulinum Neurotoxin Type A in the Treatment of Forward Head Posture with Associated Chronic Tension Type Headache using a Novel Fixed site Injection Paradigm” - 2009

Sub-Investigator - ELN115727-351 “A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Alzheimer’s Disease who Participated in Study ELN115727-301 or in Study ELN115727-302” – 2009

Sub-Investigator - DRI10566: “A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispiridine 50 mg, 100 mg, and 200 mg in Patients with Multiple Sclerosis” 2009

Sub-Investigator - 29652 “ A 12-week, Phase IIIb, Open-Label, Single-Arm, Multicenter Trial to Evaluate Ease of use of an Electronic Autoinjector (RebiSmart™) for Self-Injection in Subjects with Relapsing Multiple Sclerosis (RMS) treated with Rebif® 44mcg Subcutaneously three times a week.” - 2009

RESEARCH ACTIVITIES CONTINUED

Sub-Investigator - H9B-MC-BCDJ (a) –Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis” - 2009

Sub-Investigator - 101MS325 “A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects with Relapsing Remitting Multiple Sclerosis” – 2010

Sub-Investigator - Droxidopa NOH306 “A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Parkinson’s Disease” – 2010

Sub-Investigator - A 6-month, Randomized, Active Comparator, Open-label, Multi- Center Study to Evaluate Patient Outcomes, Safety and Tolerability of Fingolimod 0.5 mg/day in Patients with Relapsing Forms of Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy (EPOC) “ – 2010

Sub-Investigator - S187.3.002 “A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments with Parkinson Medicinal Products, who Continue to Experience Persistent Motor Fluctuations” – 2010.

Sub-Investigator - S187.3.003 “Open-Label, 12-Month Safety and Efficacy Study of Levodopa – Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson’s Disease Subjects.” – 2010.

Sub-Investigator - S187.3.004 “An Open-Label, 12 Month Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson’s Disease and Severe Motor-Fluctuations Despite Optimized Treatment with Available Parkinson’s Disease Medications” – 2010

Sub-Investigator - S187.3.005 “Open-Label Continuation Treatment Study With Levodopa – Carbidopa Intestinal Gel In Subjects With Advanced Parkinson’s Disease And Severe Motor-Fluctuation Who Have Exhibited A Persistent And Positive Effect To Treatment in Previous Studies.” – 2010.

Sub-Investigator- AAB-001-SC-ALZ-2003 “ A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects with Mild to Moderate Alzheimer’s Disease

Sub-Investigator - NTS-INT08-009 “ A double-blind, randomized, sham-controlled, parallel group, multicenter, pivotal study to assess the safety and efficacy of transcranial laser therapy with the NeuroThera® Laser System for the treatment of acute ischemic stroke within 24 hours of stroke onset.” – 2010.

Sub-Investigator - 01373 “A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset.” – 2010.

RESEARCH ACTIVITIES CONTINUED

Sub-Investigator – “0462-082-00 “ A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents” - 2010

Sub-Investigator - Study Pctcl-01373 entitled: A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset” – 2010

Sub-Investigator – RebiDose Human Factors. A three-arm multicenter trial to perform human factors testing of the investigational RebiDose ready to use single use autoinjector device including simulated injections in subjects with relapsing multiple sclerosis (RMS), caregivers, and nurses” - 2011

Sub-Investigator – FTY Prefer A 12-month, Prospective, Randomized, active-controlled, open-label study to evaluate the patient retention of Fingolimod vs. approved first-line disease modifying therapies in adults who are in early stages of treatment for Relapsing Remitting multiple sclerosis” - 2012

Sub-Investigator - Novartis Assess FTY (2312): Fingolimod vs Glatiramer Acetate
A 12-month, randomized, rater and dose-blinded study to compare the efficacy and safety of fingolimod 0.25mg and 0.5mg administered orally once daily with glatiramer acetate 20mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis” – 2012

Principle Investigator - HSC-MS-12-0210 ACTHarGel (MS) Pilot clinical trial comparing clinical efficacy of ACTHarGel 14 days SQ versus ACTHarGel five days SQ for the treatment of MS exacerbations” – 2012

Sub-Investigator – COMPEL An open-label, multicenter study of the long-term efficacy, safety, and tolerability of BOTOX for the prophylaxis of headaches in adult patients with chronic migraine” - 2012

GUIDELINES ACTIVITIES IN PROGRESS

Principle or collaborating author:

Parameter on Epilepsy and Driving: When to Drive Following a First Generalized Tonic Clonic Seizure: A Study Comparing Six-Month Interval Seizure Recurrence following a 6-Month versus 1-Year Driving Suspension

Consultant and/or Coordinator of Parameter Work Groups:

Consultant to “Guidelines for Pediatric Brain Injury.” Supported by the Brain Injury Association and the International Brain Injury Association, March 199 – Present.

Co-Chairman, “Guidelines for Mild Traumatic Brain Injury.” Supported by the Brain Injury Association and the International Brain Injury Association, November 1998 – Present.

GUIDELINES ACTIVITIES IN PROGRESS CONTINUED

Chairman, Workgroup for Acute Treatment of Migraine Headaches, April 1997 – Present.
Co-Chairman, Consortium for the Development of Practice Guidelines for Management of Migraine Headaches August 1995- Present

Consultant to the QSS Workgroup for the Management of ALS. April 1997- July 1998

AAN Representative the Brain Injury Association Working Group for the diagnosis and management of Vegetative and Minimally Conscious States.

Consultant and/or Coordinator of Parameter Work Groups:
Co-Chairman, Consortium for the establishment of Practice Guideline for Primary Headache Disorders. A consortium of the AAN, AAFP, ACEP, ASSH, and ACP.

Consultant and Representative of the American Academy of Neurology to the Consortium of the AAN, MS Consortium, and the National Multiple Sclerosis Society for the Development of Practice Guideline for the management of Multiple Sclerosis. Working groups on Fatigue and Bladder Management.

Consultant, Guideline Development Group, Lovelac Clinic, Albuquerque NM under sponsorship of CIBA Geigy, Tuesday, November 4, 1996.

Acute Head Injury Guideline, American Association of Neurological Surgeons January-December 1995.

Member, AMA Attributes Rewrite Task Force, November 9, 1995, Hotel Sofitel, Rosemont, Ill.

Coordinator for the American Academy of Neurology Subcontract for Content to Duke University for the Development of the AHCPR Guideline for Chronic Headache Pain.

Consultant, American Epilepsy Society Guidelines Meeting, March 17-19, 1995, Landsdowne Conference Center, Landsdowne, Virginia.

Facilitator, Vegetative State Workshop for Conflict Resolution at the First Annual Aspen Neurobehavioral Conference, March 29-April 2, 1995, Aspen Institute, Aspen, Colorado.

Member, Workgroup for the Persistent Vegetative State, Supported by the Royal Hospital of Putney, Hotel Gloucester, March 1-3, 1995.

Consultant, HICFA, Critical Pathways for Stroke, Fall 1994.

Consultant, CMRI Review Group, Atrial Fibrillation Study, September 30, 1994.

American Association of Neurological Surgeons/American Academy of Neurology Workshop on the Development of Practice Parameters, Chicago, January 22-25, 1993.

When to Return to Sports Following a First Concussion? Jim Kelly, M.D. Dept. of Neurology, University of Colorado Medical School.

Initial Treatment of Migraine with Ergot Medication? Steven Silberstein, M.D. and Guideline Committee of leading experts in the field of headache.

GUIDELINES ACTIVITIES IN PROGRESS CONTINUED

How do we define the Persistent Vegetative State? Multi-Specialty Group to Define a Guideline as it pertains to what constitutes the persistent vegetative State?

"Neurological Priority Setting Conference: Asst. Coordinator." Agency for Health Care Policy and Research, Rockville, Md., January 25, 1993.